Janssen Receives EC’s Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

 Janssen Receives EC’s Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Janssen Receives EC’s Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Shots:

  • The EC’s approval is based on P-III TITAN study assessing Erleada + ADT vs PBO + ADT in 1052 patients in a ratio (1:1) with mHSPC regardless of the extent of disease or prior docetaxel treatment history across 23 countries
  • The P-III TITAN study results: improvement in OS with a 33% reduction in risk of death; 52% reduction in rPFS; OS rates after a median follow up of 22.7mos. (82% vs 74%)
  • Erleada is an androgen receptor inhibitor, indicated to treat patients with nmCRPC who are at high risk of developing mHSPC in the EU

Click here ­to­ read full press release/ article | Ref: Janssen | Image: Janssen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post